In C57BL/6J mice fed an HF-HF diet, oral Sesamolin at 60 mg/kg significantly altered 16 serum metabolite biomarkers compared with the untreated HF-HF group, with 14 upregulated and 2 downregulated. In the body weight study, the same treatment significantly decreased final body weight gain compared with the untreated HF-HF group. In female BALB/c nude mice inoculated with Ishikawa cells, oral Sesamolin at 30 mg/kg and 60 mg/kg showed a suppressive effect on EC progression, as assessed by xenograft size and weight, compared with the control group. [2,3]
Sesamolin alters serum metabolic profiles in mice
Animal study · C57BL/6J mice [2]
In C57BL/6J mice fed an HF-HF diet, oral Sesamolin treatment at 60 mg/kg significantly altered 16 serum metabolite biomarkers compared with the untreated HF-HF group. Of these metabolites, 14 were upregulated and 2 were downregulated.
Conditions shared by the study groups
- Route
- orally administrated
- Treatment course
- twice a day from week 9 to week 12
- Sesamolin 60 mg/kg
- Model: C57BL/6J mice
- Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations
Compound reported in the paper: Sesamolin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.5. Sesamolin Alters Serum Metabolome in HF-HF Diet-Fed Mice (S36, S40); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S49, S56)
serum metabolic profiles: serum metabolic profiles; comparator: HF-HF group (mice fed with HF-HF diet without treatment) — 2. Results > 2.5. Sesamolin Alters Serum Metabolome in HF-HF Diet-Fed Mice (S36, S40); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S56)
Sesamolin 60 mg/kg · 2. Results > 2.5. Sesamolin Alters Serum Metabolome in HF-HF Diet-Fed Mice (S40); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S56)
Sesamolin suppresses Ishikawa xenograft progression in mice
Animal study · female BALB/c nude mice; subcutaneously inoculated with 2.0 × 106 Ishikawa cells per mouse; n = 5 [3]
In female BALB/c nude mice subcutaneously inoculated with Ishikawa cells, oral Sesamolin treatment at 30 mg/kg and 60 mg/kg showed a suppressive effect on EC progression, as assessed by xenograft size and weight, compared with the control group.
Conditions shared by the study groups
- Route
- orally administered
- Sesamolin 30 mg/kg and 60 mg/kg
- Model: female BALB/c nude mice; subcutaneously inoculated with 2.0 × 106 Ishikawa cells per mouse; n = 5
- Reported limits: Not stated in the sentences used: schedule, vehicle.
Methods and source locations
Compound reported in the paper: Sesamolin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > In vivo study (S78, S79, S80, S82); Results > Sesamolin directly targeted MYH14 to attenuate EC progression (S154, S155); Fig. 6 legend (S225, S226)
weight of xenografts: weight of xenografts; comparator: control group — Materials and methods > In vivo study (S82); Results > Sesamolin directly targeted MYH14 to attenuate EC progression (S154); Fig. 6 legend (S225)
Sesamolin 30 mg/kg and 60 mg/kg · Materials and methods > In vivo study (S82); Results > Sesamolin directly targeted MYH14 to attenuate EC progression (S154)
Sesamolin reduces body weight gain in mice
Animal study · C57BL/6J mice [2]
In C57BL/6J mice fed an HF-HF diet, oral Sesamolin treatment at 60 mg/kg significantly decreased final body weight gain compared with the untreated HF-HF group.
Conditions shared by the study groups
- Route
- orally administrated
- Treatment course
- twice a day from week 9 to week 12
- Sesamolin 60 mg/kg
- Model: C57BL/6J mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Sesamolin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.1. Sesamolin Suppresses Obesity and Metabolic Disorders in HF-HF Diet-Fed Mice (S2); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S49, S56); Figure 1 legend (S95)
Final body weight gain: Final body weight gain; comparator: HF-HF group (mice fed with HF-HF diet without treatment) — 2. Results > 2.1. Sesamolin Suppresses Obesity and Metabolic Disorders in HF-HF Diet-Fed Mice (S2); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S56); Figure 1 legend (S95)
Sesamolin 60 mg/kg · 2. Results > 2.1. Sesamolin Suppresses Obesity and Metabolic Disorders in HF-HF Diet-Fed Mice (S2); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S56)